Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Gross Margin (2018 - 2025)

Historic Gross Margin for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Q3 2025 value amounting to 82.5%.

  • Ultragenyx Pharmaceutical's Gross Margin fell 24300.0% to 82.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.69%, marking a year-over-year decrease of 15600.0%. This contributed to the annual value of 86.3% for FY2024, which is 32800.0% down from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Gross Margin stood at 82.5% for Q3 2025, which was down 24300.0% from 86.18% recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Gross Margin ranged from a high of 96.39% in Q2 2021 and a low of 79.42% during Q1 2025
  • Moreover, its 5-year median value for Gross Margin was 90.48% (2022), whereas its average is 89.5%.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Gross Margin skyrocketed by 44300bps in 2021 and then tumbled by -56500bps in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Gross Margin (Quarter) stood at 95.79% in 2021, then dropped by -1bps to 94.85% in 2022, then fell by -5bps to 90.54% in 2023, then fell by -1bps to 89.75% in 2024, then dropped by -8bps to 82.5% in 2025.
  • Its Gross Margin stands at 82.5% for Q3 2025, versus 86.18% for Q2 2025 and 79.42% for Q1 2025.